LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

RadNet to Present at the Sidoti & Company Fall 2023 Virtual Conference on Wednesday, September 20th

September 20, 2023 | Last Trade: US$73.81 2.09 2.91

LOS ANGELES, Sept. 20, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Fall 2023 Conference on Wednesday, September 20th at 4:00 p.m. Eastern Time.

There will be simultaneous and archived webcasts available at https://sidoti.zoom.us/webinar/register/WN_1qNfmm8xQX6AHwKesZ3aJw
and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.

Details for RadNet's Presentation:

Date:Wednesday, September 20, 2023
Time:4:00 p.m. Eastern Time
URL:https://sidoti.zoom.us/webinar/register/WN_1qNfmm8xQX6AHwKesZ3aJw

About RadNet, Inc.

RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 363 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of approximately 9,000 employees. For more information, visit http://www.radnet.com.

Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928

 


Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page